What medication can suppress premature ventricular contractions (PVCs) without decreasing heart rate in a patient without structural heart disease, coronary artery disease, or heart failure?

Flecainide or Propafenone for PVC Suppression Without Heart Rate Reduction

For patients with symptomatic PVCs and no structural heart disease, flecainide is the most effective medication that suppresses PVCs without decreasing heart rate, with propafenone as an alternative class IC agent.

Rationale and Evidence Hierarchy

The 2017 AHA/ACC/HRS guidelines 1 establish the critical framework: class I sodium channel blockers are contraindicated in patients with structural heart disease, post-MI, or reduced LVEF due to increased mortality risk (as demonstrated in the CAST trials). However, in patients WITHOUT these conditions, class IC agents become viable options.

Why Class IC Agents (Flecainide/Propafenone)?

Flecainide demonstrates superior PVC suppression without negative chronotropic effects:

• Recent 2026 case data 2 showed flecainide achieved complete suppression of short-coupled PVCs triggering ventricular fibrillation after amiodarone and esmolol (a beta-blocker that reduces heart rate) failed
• A 2018 study 3 demonstrated flecainide/propafenone reduced PVC burden from 36.2% to 10.0% (P<0.001) in suspected PVC-induced cardiomyopathy, with LVEF improvement from 37.4% to 49.0%
• A 2012 prospective crossover study 4 directly compared agents: propafenone was most effective (42% responders), followed by verapamil (15%), then metoprolol (10%)

Mechanism: No Heart Rate Reduction

Unlike beta-blockers (metoprolol) or calcium channel blockers (verapamil), class IC agents work by:

• Blocking fast sodium channels in ventricular tissue
• Slowing conduction velocity without significant effects on sinus node automaticity
• No direct negative chronotropic effect on heart rate

Alternative Consideration: Ranolazine

Ranolazine offers another non-rate-reducing option 5:

• Reduced PVCs by 71% (13,329 to 3,837 beats/day, P<0.001)
• Suppresses triggered ectopy via EAD/DAD inhibition
• Does not reduce heart rate (works via late sodium current inhibition)
• Dose-dependent effect (500-1000mg daily)
• 95% of patients showed PVC reduction

Critical Safety Screening Required

Before prescribing class IC agents, you MUST exclude:

1. Structural heart disease (echocardiography mandatory)
2. Coronary artery disease (stress testing if risk factors present)
3. Reduced LVEF (<50%)
4. Prior myocardial infarction
5. QRS prolongation (>120ms baseline)

The guidelines 1 explicitly warn that class IC agents increase mortality in these populations.

Practical Algorithm

Step 1: Confirm no structural heart disease via echocardiography (LVEF ≥50%, no wall motion abnormalities)

Step 2: First-line: Flecainide 50-100mg twice daily (titrate based on response)

• Alternative: Propafenone 150-300mg three times daily

Step 3: Monitor ECG for QRS widening (discontinue if QRS increases >25% from baseline)

Step 4: If ineffective or not tolerated, consider ranolazine 500-1000mg daily

Step 5: If medical therapy fails, catheter ablation (88% long-term success rate 4)

Common Pitfalls to Avoid

• Never use class IC agents without excluding structural heart disease first - this is the CAST trial lesson 1
• Don't confuse "benign PVCs" with "safe for any medication" - the medication choice matters more than PVC characteristics
• Avoid beta-blockers if heart rate reduction is undesirable (only 10% response rate anyway 4)
• Don't use amiodarone as first-line - it has significant long-term toxicity and was ineffective in the case where flecainide succeeded 2

The evidence strongly supports class IC agents (flecainide preferred) as the optimal choice for PVC suppression without heart rate effects in structurally normal hearts.